Business Context and Reporting Period
This Form 8-K is a current report filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc. as indicated in metadata) on February 3, 2012, covering events occurring on January 30, 2012. The company is incorporated in Nevada and operates from Englewood Cliffs, New Jersey.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
On January 30, 2012, the Board of Directors removed Daniel Fisher from the Board and from his position as Executive Vice President. No other material financial or operational changes were reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document strictly reports the departure of a director and officer.
Investor Verification Checklist
- Verify the reason for Daniel Fisher's removal from the Board and Executive Vice President role.
- Confirm if there are any pending legal disputes or compensation claims related to Mr. Fisher's departure.
- Check subsequent filings for the appointment of a replacement Executive Vice President.
- Review the company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains none.